Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-03-27

Clinical Trial Update: Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update reports long-term effectiveness and safety data for CP-690,550 in rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2018-03-27